GlassScriptPhysician profile
Maria E Perez Grau
NPI 1821065855
$10,992.48
in general payments reported to CMS, 2019-2025
36 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,035 · 2020: $1,653 · 2021: $1,176 · 2022: $253 · 2023: $2,773 · 2024: $983 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,967 · Consulting Fee: $1,638 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,966.57 |
| Consulting Fee | $1,638.00 |
| Education | $271.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,866.32 | 2019-2025 | Opdivo, Breyanzi, Opdualag |
| Astrazeneca Pharmaceuticals LP | $1,428.10 | 2019-2025 | Tagrisso, Imfinzi, Calquence |
| Eli Lilly Export S.A. Puerto Rico Branch | $954.26 | 2019-2025 | Jaypirca, Verzenio |
| Abbvie INC. | $837.75 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $780.61 | 2019-2025 | Erleada, Xarelto, Darzalex |
| Pbg Puerto Rico LLC | $614.23 | 2019-2025 | |
| Genentech USA, INC. | $525.39 | 2019-2025 | Polivy, Lunsumio, Itovebi |
| Merck Sharp & Dohme LLC | $522.11 | 2019-2025 | Keytruda, Keytruda Qlex |
| Amgen INC. | $441.39 | 2019-2025 | Xgeva, Kyprolis, Lumakras |
| Incyte Corporation | $206.53 | 2021-2025 | Monjuvi, Pemazyre, Jakafi |
| Genzyme Corporation | $185.88 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $184.45 | 2019-2025 | |
| Glaxosmithkline, LLC. | $166.44 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $153.73 | 2020-2022 | |
| Celgene Corporation | $145.59 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Puerto Rico INC. | $121.53 | 2023-2025 | Nubeqa, Stivarga, Vitrakvi |
| Pfizer Pharmaceuticals LLC | $114.97 | 2019 | |
| Boston Scientific Corporation | $112.02 | 2022 | |
| Janssen Biotech, INC. | $76.95 | 2020 | |
| Abbott Laboratories | $58.93 | 2019 | |
| Eisai INC. | $46.46 | 2019 | |
| Karyopharm Therapeutics INC. | $45.87 | 2023-2024 | Xpovio |
| Lantheus Medical Imaging, INC. | $44.33 | 2019 | |
| Immunogen, INC. | $41.75 | 2023 | Elahere |
| Ferring Pharmaceuticals INC. | $39.21 | 2019 | |
| Taiho Oncology, INC. | $34.64 | 2019 | |
| Adaptive Biotechnologies Corporation | $32.70 | 2023 | Clonoseq |
| Exelixis INC. | $31.06 | 2019 | |
| Rigel Pharmaceuticals, INC. | $30.29 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $29.11 | 2019 | |
| Clovis Oncology, INC. | $27.35 | 2019 | |
| Pfizer INC. | $25.38 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.30 | 2023 | Libtayo |
| Sanofi-Aventis U.S. LLC | $24.59 | 2021 | |
| Puma Biotechnology, INC. | $16.26 | 2020 | |
| Lilly USA, LLC | $1.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Perez Grau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.